US court rejects Novo Nordisk's challenge to Medicare drug pricing plan

Core Viewpoint - A federal appeals court has upheld the U.S. government's program allowing Medicare to negotiate lower drug prices, rejecting Novo Nordisk's challenge [1] Group 1: Company Impact - Novo Nordisk's challenge to the Medicare negotiation program has been rejected, which may impact its pricing strategy and revenue from Medicare patients [1] Group 2: Industry Implications - The ruling reinforces the government's ability to negotiate drug prices, potentially leading to lower costs for consumers and affecting the overall pharmaceutical industry pricing dynamics [1]